GB0228723D0 - Treatment of pain - Google Patents

Treatment of pain

Info

Publication number
GB0228723D0
GB0228723D0 GBGB0228723.3A GB0228723A GB0228723D0 GB 0228723 D0 GB0228723 D0 GB 0228723D0 GB 0228723 A GB0228723 A GB 0228723A GB 0228723 D0 GB0228723 D0 GB 0228723D0
Authority
GB
United Kingdom
Prior art keywords
treatment
pain
methoxyadenosine
spongosine
adenosines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0228723.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Biotechnology Ltd
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Priority to GBGB0228723.3A priority Critical patent/GB0228723D0/en
Publication of GB0228723D0 publication Critical patent/GB0228723D0/en
Priority to AU2003288451A priority patent/AU2003288451B2/en
Priority to ES03780370T priority patent/ES2326532T3/es
Priority to JP2004558826A priority patent/JP4836454B2/ja
Priority to CNB2003801055073A priority patent/CN100471503C/zh
Priority to US10/537,564 priority patent/US8252766B2/en
Priority to EP03780370A priority patent/EP1581235B1/en
Priority to DE60327557T priority patent/DE60327557D1/de
Priority to CN2008100922507A priority patent/CN101264097B/zh
Priority to PCT/GB2003/005379 priority patent/WO2004052377A1/en
Priority to SI200331633T priority patent/SI1581235T1/sl
Priority to KR1020057010441A priority patent/KR101122495B1/ko
Priority to HK06106093.7A priority patent/HK1086186B/xx
Priority to GB0328548A priority patent/GB2396108B/en
Priority to DK03780370T priority patent/DK1581235T3/da
Priority to PT03780370T priority patent/PT1581235E/pt
Priority to AT03780370T priority patent/ATE430572T1/de
Priority to NZ540353A priority patent/NZ540353A/en
Priority to CA002507918A priority patent/CA2507918A1/en
Priority to NO20053042A priority patent/NO20053042L/no
Priority to CY20091100733T priority patent/CY1109229T1/el
Priority to US12/859,932 priority patent/US20110184065A1/en
Priority to JP2010270287A priority patent/JP2011132229A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0228723.3A 2002-12-09 2002-12-09 Treatment of pain Ceased GB0228723D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB0228723.3A GB0228723D0 (en) 2002-12-09 2002-12-09 Treatment of pain
CA002507918A CA2507918A1 (en) 2002-12-09 2003-12-09 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia
SI200331633T SI1581235T1 (sl) 2002-12-09 2003-12-09 Uporaba spongozin (2-metoksiadenozeina) za zdravljenje bolečine, zlasti hiperalgezije
HK06106093.7A HK1086186B (en) 2002-12-09 2003-12-09 Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
JP2004558826A JP4836454B2 (ja) 2002-12-09 2003-12-09 疼痛、特に痛覚過敏治療のための、スポンゴシン（２−メトキシアデノシン）の使用。
CNB2003801055073A CN100471503C (zh) 2002-12-09 2003-12-09 海绵核苷（2-甲氧腺苷）在制备治疗疼痛的药物中的用途
US10/537,564 US8252766B2 (en) 2002-12-09 2003-12-09 Use of spongosine for the treatment of pain
EP03780370A EP1581235B1 (en) 2002-12-09 2003-12-09 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia
DE60327557T DE60327557D1 (de) 2002-12-09 2003-12-09 Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
CN2008100922507A CN101264097B (zh) 2002-12-09 2003-12-09 海绵核苷作为镇痛剂的用途
PCT/GB2003/005379 WO2004052377A1 (en) 2002-12-09 2003-12-09 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia
AU2003288451A AU2003288451B2 (en) 2002-12-09 2003-12-09 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia
KR1020057010441A KR101122495B1 (ko) 2002-12-09 2003-12-09 통증, 특히 통각과민의 치료를 위한스퐁고신（2-메톡시아데노세인）의 용도
ES03780370T ES2326532T3 (es) 2002-12-09 2003-12-09 Uso de espongosina (2-metoxidenoseina) para el tratamiento del dolor, en particular de la hieralgesia.
GB0328548A GB2396108B (en) 2002-12-09 2003-12-09 Treatment of pain
DK03780370T DK1581235T3 (da) 2002-12-09 2003-12-09 Anvendelse af spongosin (2-methoxyadenosin) til behandling af smerte i særdeleshed hyperalgesi
PT03780370T PT1581235E (pt) 2002-12-09 2003-12-09 Utilização de espongosina (2-metoxiadenoseína) para o tratamento de dor, em particular hiperalgesia
AT03780370T ATE430572T1 (de) 2002-12-09 2003-12-09 Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
NZ540353A NZ540353A (en) 2002-12-09 2003-12-09 Spongosine for inhibiting pain perception from neuropathic and inflammatory pain even when administered at doses expected to give concentrations well below those known to activate adenosine receptors
NO20053042A NO20053042L (no) 2002-12-09 2005-06-21 Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
CY20091100733T CY1109229T1 (el) 2002-12-09 2009-07-14 Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
US12/859,932 US20110184065A1 (en) 2002-12-09 2010-08-20 Use of spongosine for the treatment of pain
JP2010270287A JP2011132229A (ja) 2002-12-09 2010-12-03 疼痛、特に痛覚過敏治療のための、スポンゴシン（２−メトキシアデノシン）の使用。

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228723.3A GB0228723D0 (en) 2002-12-09 2002-12-09 Treatment of pain

Publications (1)

Publication Number Publication Date
GB0228723D0 true GB0228723D0 (en) 2003-01-15

Family

ID=9949371

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0228723.3A Ceased GB0228723D0 (en) 2002-12-09 2002-12-09 Treatment of pain
GB0328548A Expired - Fee Related GB2396108B (en) 2002-12-09 2003-12-09 Treatment of pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0328548A Expired - Fee Related GB2396108B (en) 2002-12-09 2003-12-09 Treatment of pain

Country Status (18)

Country Link
US (2) US8252766B2 (https=)
EP (1) EP1581235B1 (https=)
JP (2) JP4836454B2 (https=)
KR (1) KR101122495B1 (https=)
CN (2) CN101264097B (https=)
AT (1) ATE430572T1 (https=)
AU (1) AU2003288451B2 (https=)
CA (1) CA2507918A1 (https=)
CY (1) CY1109229T1 (https=)
DE (1) DE60327557D1 (https=)
DK (1) DK1581235T3 (https=)
ES (1) ES2326532T3 (https=)
GB (2) GB0228723D0 (https=)
NO (1) NO20053042L (https=)
NZ (1) NZ540353A (https=)
PT (1) PT1581235E (https=)
SI (1) SI1581235T1 (https=)
WO (1) WO2004052377A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
CA2557285A1 (en) * 2004-03-05 2005-09-15 Cambridge Biotechnology Limited Adenosine receptor agonists
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2008000743A2 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
BRPI0713902A2 (pt) 2006-06-27 2012-11-27 Biovitrum Ab compostos terapêuticos
AU2007263728A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Adenosine derivatives for the treatment of pain
JP2011509305A (ja) * 2008-01-09 2011-03-24 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療
US8221791B1 (en) 2008-12-10 2012-07-17 University Of Central Florida Research Foundation, Inc. Silica-based antibacterial and antifungal nanoformulation
US20120165285A1 (en) * 2009-07-09 2012-06-28 Peter Richardson Combined preparation for use as a medicament
US20130123208A1 (en) * 2010-05-12 2013-05-16 The Regents of the University of Colorado, a body corporation Method of treating multiple sclerosis with adenosine receptor agonists
EP2631345B1 (en) * 2012-02-27 2019-09-04 Electrolux Home Products Corporation N.V. Washing tub unit and washing machine
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
US10774110B2 (en) * 2016-02-04 2020-09-15 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792155A (fr) 1971-12-01 1973-05-30 Takeda Chemical Industries Ltd Nouveaux derives de l'adenosine et leur procede de production
JPS4861498A (https=) 1971-12-01 1973-08-28
DE2359536C2 (de) * 1972-12-08 1984-08-02 Takeda Chemical Industries, Ltd., Osaka 2,6-Diaminonebularinderivate
JPS5549594B2 (https=) 1972-12-08 1980-12-12
JPS5461194A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
JPS5461195A (en) 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
US4705758A (en) * 1984-06-19 1987-11-10 Warner-Lambert Company Adenosine receptor assay and kit
US5231086A (en) * 1985-09-24 1993-07-27 Item Development Aktiebolag Continuous administration adenosine to increase myocardial blood flow
US5104859A (en) * 1985-09-24 1992-04-14 Solimedco Aktiebolag Continuous administration of adenosine to reduce pulmonary vascular resistance
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US6180616B1 (en) * 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
WO1994023723A1 (en) 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
SE9401499D0 (sv) 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
AU2546195A (en) 1994-05-10 1995-11-29 Novartis Ag Adenosine derivatives
US5596094A (en) * 1994-05-26 1997-01-21 Sandoz Ltd. Process for preparing 2' -0- alkyl adenosine derivatives
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
AU7449598A (en) 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
JP2002500188A (ja) 1998-01-08 2002-01-08 ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション Ａ２ａアデノシンレセプター作動因子
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
CA2551169A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
CA2557285A1 (en) 2004-03-05 2005-09-15 Cambridge Biotechnology Limited Adenosine receptor agonists
US8407664B2 (en) 2005-12-30 2013-03-26 Sap Ag Software model business objects

Also Published As

Publication number Publication date
JP4836454B2 (ja) 2011-12-14
EP1581235B1 (en) 2009-05-06
CN101264097B (zh) 2011-10-05
GB0328548D0 (en) 2004-01-14
WO2004052377A1 (en) 2004-06-24
NZ540353A (en) 2006-11-30
US20110184065A1 (en) 2011-07-28
CN100471503C (zh) 2009-03-25
EP1581235A1 (en) 2005-10-05
KR101122495B1 (ko) 2012-03-15
US8252766B2 (en) 2012-08-28
CY1109229T1 (el) 2013-09-04
GB2396108A (en) 2004-06-16
JP2006514638A (ja) 2006-05-11
AU2003288451A1 (en) 2004-06-30
DK1581235T3 (da) 2009-08-31
CN101264097A (zh) 2008-09-17
SI1581235T1 (sl) 2009-10-31
DE60327557D1 (de) 2009-06-18
HK1086186A1 (zh) 2006-09-15
GB2396108B (en) 2005-08-03
PT1581235E (pt) 2009-07-07
AU2003288451B2 (en) 2009-06-04
KR20050089815A (ko) 2005-09-08
ES2326532T3 (es) 2009-10-14
JP2011132229A (ja) 2011-07-07
US20070010475A1 (en) 2007-01-11
CN1723026A (zh) 2006-01-18
CA2507918A1 (en) 2004-06-24
ATE430572T1 (de) 2009-05-15
NO20053042L (no) 2005-06-21

Similar Documents

Publication Publication Date Title
GB2396108B (en) Treatment of pain
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
GB0305149D0 (en) Compounds for the treatment of pain
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
MXPA05006359A (es) Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005023179A3 (en) Combination methods of treating cancer
HRP20041071A2 (en) Methods of treating hepatitis
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
MXPA05006628A (es) Tratamiento de insuficiencia cardiaca cronica.
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
GB0209262D0 (en) Organic compounds
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
GB2400556B (en) Therapeutic composition for autoimmune conditions
WO2008060381A3 (en) Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
MY118982A (en) Method of reducing tissue damage associated with ischemia

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)